Interested in applying?
We’re always looking for new talent from different backgrounds (data analysis, hematology, epigenetics, and more).
Product research: Help drive our research and development forward towards our transformation.
Control mechanisms of tobacco leaf senescence: Delve into plant genetics and investigate the processes behind cell aging in tobacco plants.
Measuring protein adducts in blood samples: Extract and validate biochemical complexes and biomarkers in the blood.
Establishing “SensoCytes” using human progenitor cells or iPSCs: Investigate SensoCytes – genetically engineered cells with intracellular sensors.
Assessing neuroinflammation, using iPSC-derived in vitro models: Use biological network models and in vitro co-cultures to examine neuroinflammation pathways.
Mechanistic investigations on tobacco plants to understand aerosol chemistry relationships: Develop models on the relationship between plant precursors and aerosol chemistry.
Aerosol phase distribution and interactions: Dive into particle and gas-vapor phase distributions to support our engineering testing teams.
Artificial Intelligence (AI) in systems toxicology: Work on innovative applications for neuronal networks to bring AI further into life sciences.
Translational systems biology for new mechanistic disease risk biomarker discovery: Collaborate with our Singapore scientists to design an in vivo study for biomarker research.
Breathomics: Analyzing chemical compounds from exhaled breath: Identify and analyze chemical and biological markers in breath.
Our aim at PMI Science
Although smoking rates are declining in many countries, it is estimated that by 2020, the worldwide number of smokers will exceed 1 billion. Providing alternative reduced risk products (RRPs) for smokers who would otherwise continue to smoke is our focus at PMI Science. We’re developing novel RRPs that, we believe, will be acceptable to current adult smokers, and with a risk profile that is significantly lower than cigarettes.
In order to assess whether switching to these novel products can reduce the risk of developing the diseases most strongly associated with smoking, when compared to continued smoking, we have developed a comprehensive and extensive scientific assessment program.